Turn Biotechnologies Acquires ARMMs Tech for Epigenetic Therapies
March 26, 2025
ARMMs brings precision medicine through targeted, non-viral vesicular delivery. Turn Biotechnologies, a pioneer in epigenetic reprogramming, announced the acquisition of groundbreaking ARMMs (ARRDC1 Mediated Microvesicles)